Clinical Trial Update: NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NAP in combination with docetaxel after obinutuzumab pretreatment in advanced or metastatic non-small cell lung cancer. Results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• NAP
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: NeoTX Therapeutics Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-03-03